-
A Centers for Medicare & Medicaid Services draft infection control survey expected to be finalized for use in hospitals next year could lead to increased support and appreciation for the challenges faced by central services departments, says Rose Seavey, RN, BS, MBA, CNOR, CRCST, CSPDT, President/CEO of Seavey Healthcare Consulting, Inc., in Arvada, CO.
-
The Centers for Disease Control and Prevention is trying to overcome some stubborn myths and misperceptions about single-dose vials including the following, which the agency refuted with the current facts.
-
In what is getting to be a familiar, tragic refrain, the improper use of single-dose vials recently resulted in patients at pain clinics in Arizona and Delaware acquiring serious bacterial infections that were "completely preventable," the Centers for Disease Control and Prevention reports.
-
In light of recurrent outbreaks linked to misuse of single-dose medication vials, the Centers for Disease Control and Prevention is emphasizing that medications labeled as "single dose" or "single use" are to be used for only one patient.
-
Looking for a quality improvement (QI) project targeting catheter-associated urinary tract infections (CAUTIs)? Here's one that produced dramatic results, including a 68% decline in the CAUTI rate and a 20% reduction in the use of indwelling urinary catheters.
-
This study was a secondary analysis of data from an earlier randomized clinical trial comparing one antibiotic vs two (meropenem alone or meropenem plus ciprofloxacin) as early empiric therapy for ventilator-associated pneumonia (VAP).
-
-
In a recent discussion of a clinical case in the New England Journal of Medicine, the authors correctly indicate itraconazole is recommended for all but the most severe cases of disseminated histoplasmosis (when amphotericin B is used).
-
This ProMED-mail alert describes the case of a young Rhode Island resident who traveled to Cambodia and Viet Nam, where she was hospitalized with spinal cord compression in December 2011.
-
A total of 1745 infants from 17 sites in Brazil (70.1%), South Africa (27.4%), Argentina (1.6%) and the United States (0.8%) born to women with a peripartum diagnosis of HIV type I infection were randomized within 48 hours of birth to receive one of three six-week postpartum antiretroviral regimens.